Log in

NASDAQ:HALOHalozyme Therapeutics News Headlines

$16.25
-0.62 (-3.68 %)
(As of 04/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$16.11
Now: $16.25
$16.94
50-Day Range
$13.88
MA: $18.77
$21.83
52-Week Range
$12.71
Now: $16.25
$22.06
Volume704,596 shs
Average Volume2.16 million shs
Market Capitalization$2.24 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.71

Headlines

Halozyme Therapeutics (NASDAQ HALO) News Headlines

Source:
DateHeadline
Halozyme Announces Change Of Location Of Annual Stockholders MeetingHalozyme Announces Change Of Location Of Annual Stockholders' Meeting
www.prnewswire.com - April 3 at 4:23 PM
Halozyme Announces Change Of Location Of Annual Stockholders' MeetingHalozyme Announces Change Of Location Of Annual Stockholders' Meeting
finance.yahoo.com - April 3 at 4:23 PM
Osiris Therapeutics (OTCMKTS:OSIR) versus Halozyme Therapeutics (OTCMKTS:HALO) Head to Head ReviewOsiris Therapeutics (OTCMKTS:OSIR) versus Halozyme Therapeutics (OTCMKTS:HALO) Head to Head Review
www.americanbankingnews.com - April 3 at 8:54 AM
Analyzing Halozyme Therapeutics (NASDAQ:HALO) & Eiger Biopharmaceuticals (NASDAQ:EIGR)Analyzing Halozyme Therapeutics (NASDAQ:HALO) & Eiger Biopharmaceuticals (NASDAQ:EIGR)
www.americanbankingnews.com - April 1 at 3:15 PM
 Brokerages Anticipate Halozyme Therapeutics, Inc. (NASDAQ:HALO) Will Announce Quarterly Sales of $39.35 Million Brokerages Anticipate Halozyme Therapeutics, Inc. (NASDAQ:HALO) Will Announce Quarterly Sales of $39.35 Million
www.americanbankingnews.com - March 31 at 2:56 AM
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Buy" by AnalystsHalozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - March 30 at 8:18 PM
Halozyme Therapeutics, Inc. (HALO): Are Hedge Funds Right About This Stock?Halozyme Therapeutics, Inc. (HALO): Are Hedge Funds Right About This Stock?
finance.yahoo.com - March 29 at 9:42 PM
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Expected to Post Earnings of -$0.01 Per ShareHalozyme Therapeutics, Inc. (NASDAQ:HALO) Expected to Post Earnings of -$0.01 Per Share
www.americanbankingnews.com - March 29 at 4:44 PM
2019 Review: Detailed Polymer-Based Drug Delivery Market Global Scenario and Development Activity2019 Review: Detailed Polymer-Based Drug Delivery Market Global Scenario and Development Activity
www.marketwatch.com - March 29 at 4:42 PM
First Week of May 15th Options Trading For Halozyme Therapeutics (HALO)First Week of May 15th Options Trading For Halozyme Therapeutics (HALO)
www.nasdaq.com - March 27 at 3:26 PM
Halozyme Therapeutics Inc.Halozyme Therapeutics Inc.
www.barrons.com - March 26 at 10:28 PM
Halozyme Therapeutics (HALO) Down 20.1% Since Last Earnings Report: Can It Rebound?Halozyme Therapeutics (HALO) Down 20.1% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - March 25 at 3:37 PM
Kenneth J. Kelley Buys 52,629 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) StockKenneth J. Kelley Buys 52,629 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock
www.americanbankingnews.com - March 19 at 9:51 PM
Is Halozyme Therapeutics (HALO) Stock a Solid Choice Right Now?Is Halozyme Therapeutics (HALO) Stock a Solid Choice Right Now?
finance.yahoo.com - March 19 at 2:17 PM
Antidiabetics Market 2020 Global Analysis, Opportunities and Forecast to 2025Antidiabetics Market 2020 Global Analysis, Opportunities and Forecast to 2025
www.marketwatch.com - March 19 at 9:17 AM
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Short Interest Up 7.9% in FebruaryHalozyme Therapeutics, Inc. (NASDAQ:HALO) Short Interest Up 7.9% in February
www.americanbankingnews.com - March 15 at 2:53 PM
Halozyme Therapeutics is Now Oversold (HALO)Halozyme Therapeutics is Now Oversold (HALO)
www.nasdaq.com - March 13 at 2:25 PM
Breast Cancer Therapeutics Market 2020 Segmentation, Application and Analysis Research Report To 2026Breast Cancer Therapeutics Market 2020 Segmentation, Application and Analysis Research Report To 2026
www.marketwatch.com - March 11 at 8:57 AM
Surging Earnings Estimates Signal Good News for Halozyme (HALO)Surging Earnings Estimates Signal Good News for Halozyme (HALO)
finance.yahoo.com - February 28 at 12:54 PM
Halozyme Therapeutics, Inc. 2019 Q4 - Results - Earnings Call PresentationHalozyme Therapeutics, Inc. 2019 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 28 at 7:53 AM
Halozyme Therapeutics, Inc. Just Released Its Annual Results And Analysts Are Updating Their EstimatesHalozyme Therapeutics, Inc. Just Released Its Annual Results And Analysts Are Updating Their Estimates
finance.yahoo.com - February 27 at 9:19 AM
Halozyme Therapeutics To Present At The Cowen 40th Annual Health Care ConferenceHalozyme Therapeutics To Present At The Cowen 40th Annual Health Care Conference
finance.yahoo.com - February 26 at 5:55 PM
Halozyme Announces FDA Has Accepted Biologics License Application For Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Enhanze® TechnologyHalozyme Announces FDA Has Accepted Biologics License Application For Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Enhanze® Technology
finance.yahoo.com - February 25 at 9:16 AM
Edited Transcript of HALO earnings conference call or presentation 24-Feb-20 9:30pm GMTEdited Transcript of HALO earnings conference call or presentation 24-Feb-20 9:30pm GMT
finance.yahoo.com - February 25 at 9:16 AM
Halozyme Therapeutics Inc (HALO) Q4 2019 Earnings Call TranscriptHalozyme Therapeutics Inc (HALO) Q4 2019 Earnings Call Transcript
www.fool.com - February 24 at 10:46 PM
BRIEF-Halozyme Says Elaine Sun Has Been Appointed CFOBRIEF-Halozyme Says Elaine Sun Has Been Appointed CFO
www.reuters.com - February 24 at 7:01 PM
Halozyme -1.5% as Q4 report missesHalozyme -1.5% as Q4 report misses
seekingalpha.com - February 24 at 7:01 PM
Halozyme Therapeutics EPS misses by $0.06, misses on revenueHalozyme Therapeutics EPS misses by $0.06, misses on revenue
seekingalpha.com - February 24 at 7:01 PM
Halozyme Announces CFO TransitionHalozyme Announces CFO Transition
finance.yahoo.com - February 24 at 7:01 PM
Halozyme Reports Fourth Quarter and Full Year 2019 ResultsHalozyme Reports Fourth Quarter and Full Year 2019 Results
finance.yahoo.com - February 24 at 7:01 PM
Halozyme Therapeutics (HALO) Reports Q4 Loss, Lags Revenue EstimatesHalozyme Therapeutics (HALO) Reports Q4 Loss, Lags Revenue Estimates
finance.yahoo.com - February 24 at 7:01 PM
Halozyme Therapeutics Q4 2019 Earnings PreviewHalozyme Therapeutics Q4 2019 Earnings Preview
seekingalpha.com - February 23 at 5:47 PM
Earnings Preview: Halozyme Therapeutics (HALO) Q4 Earnings Expected to DeclineEarnings Preview: Halozyme Therapeutics (HALO) Q4 Earnings Expected to Decline
finance.yahoo.com - February 17 at 5:36 PM
Halozyme To Host Fourth Quarter And Full Year 2019 Financial Results Webcast And Conference CallHalozyme To Host Fourth Quarter And Full Year 2019 Financial Results Webcast And Conference Call
finance.yahoo.com - February 10 at 5:54 PM
Is Halozyme Therapeutics (NASDAQ:HALO) Using Debt In A Risky Way?Is Halozyme Therapeutics (NASDAQ:HALO) Using Debt In A Risky Way?
finance.yahoo.com - February 6 at 1:11 PM
BRIEF-Halozyme Sees FY 2020 Revenue Between $230 Mln To $245 MlnBRIEF-Halozyme Sees FY 2020 Revenue Between $230 Mln To $245 Mln
www.msn.com - January 14 at 4:02 PM
Halozyme Provides 2020 Business Update And Financial GuidanceHalozyme Provides 2020 Business Update And Financial Guidance
finance.yahoo.com - January 14 at 4:02 PM
Mirati adds management depth ahead of commercial launchesMirati adds management depth ahead of commercial launches
seekingalpha.com - January 6 at 5:17 PM
BRIEF-Halozyme Therapeutics Says Global Phase III FeDeriCa Study Met Primary EndpointBRIEF-Halozyme Therapeutics Says Global Phase III FeDeriCa Study Met Primary Endpoint
www.msn.com - December 12 at 10:06 PM
Why Is Halozyme Therapeutics (HALO) Up 6.1% Since Last Earnings Report?Why Is Halozyme Therapeutics (HALO) Up 6.1% Since Last Earnings Report?
finance.yahoo.com - December 12 at 5:06 PM
Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer SymposiumData From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium
finance.yahoo.com - December 12 at 7:05 AM
Gallbladder Cancer Treatment Market Boosting the Healthcare Industry Worldwide | Advenchen Laboratories LLC, Array BioPharma, Bayer AGGallbladder Cancer Treatment Market Boosting the Healthcare Industry Worldwide | Advenchen Laboratories LLC, Array BioPharma, Bayer AG
www.marketwatch.com - December 6 at 2:38 PM
Edited Transcript of HALO earnings conference call or presentation 12-Nov-19 9:30pm GMTEdited Transcript of HALO earnings conference call or presentation 12-Nov-19 9:30pm GMT
finance.yahoo.com - November 18 at 11:19 PM
Halozyme Therapeutics (HALO) Looks Good: Stock Adds 5.4% in SessionHalozyme Therapeutics (HALO) Looks Good: Stock Adds 5.4% in Session
finance.yahoo.com - November 14 at 1:10 PM
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $400 Million of Convertible Senior Notes due 2024
www.prnewswire.com - November 13 at 11:43 PM
Halozyme Therapeutics Inc (HALO) Q3 2019 Earnings Call TranscriptHalozyme Therapeutics Inc (HALO) Q3 2019 Earnings Call Transcript
www.nasdaq.com - November 12 at 11:01 PM
Halozyme Therapeutics EPS misses by $0.05, misses on revenueHalozyme Therapeutics EPS misses by $0.05, misses on revenue
seekingalpha.com - November 12 at 6:00 PM
Bernadette Connaughton Appointed to Syneos Health Board of DirectorsBernadette Connaughton Appointed to Syneos Health Board of Directors
finance.yahoo.com - November 12 at 6:00 PM
Halozyme Therapeutics, Inc. Announces Proposed Offering of $400 Million of Convertible Senior Notes due 2024Halozyme Therapeutics, Inc. Announces Proposed Offering of $400 Million of Convertible Senior Notes due 2024
www.prnewswire.com - November 12 at 4:24 PM
Halozyme Therapeutics, Inc. Common Stock (HALO) Earnings Report DateHalozyme Therapeutics, Inc. Common Stock (HALO) Earnings Report Date
www.nasdaq.com - November 12 at 7:51 AM
This page was last updated on 4/5/2020 by MarketBeat.com Staff

Featured Article: Capital Gains Distribution

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel